| Bioactivity | GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM. | |||||||||
| Target | IC50: 5 μ M (NOX4, cell assay), 40 μM (NOX2, cell assay) | |||||||||
| Invitro | GLX351322 is an inhibitor of NADPH oxidase 4, and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM. GLX351322 shows weak activity against NOX2 in hPBMC cells (IC50, 40 μM). | |||||||||
| In Vivo | GLX351322 (3.8 mg/kg/day, p.o.) ameliorates HFD-induced hyperglycemia in mice[1]. | |||||||||
| Name | GLX351322 | |||||||||
| CAS | 835598-94-2 | |||||||||
| Formula | C21H25N3O5S | |||||||||
| Molar Mass | 431.51 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Anvari E, et al. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radic Res. 2015;49(11):1308-18. |
GLX351322
CAS: 835598-94-2 F: C21H25N3O5S W: 431.51
GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.